[{"data":1,"prerenderedAt":392},["ShallowReactive",2],{"report:en:ace-strategy":3},{"schemaVersion":4,"locale":5,"direction":6,"routeId":7,"slug":8,"title":9,"source":10,"sourceSections":14},"1.0.0","en","ltr","ace-strategy","strategy\u002Face","ACE Strategy",{"authority":11,"documentName":12,"sha256":13},"official-locale-idml","افالون فارما - التقرير السنوي english 2025 v3.20.indd","297bf7518216874132615aafd4aa637a92908ea1b50f6ee659ee25b8a368e0ea",[15],{"id":7,"title":16,"preview":17,"stories":20},"Avalon’s “ACE” Strategy:",[18,19],"Avalon is committed to implementing its “ACE” strategy, which forms the cornerstone of its vision to become a رbillion leading pharmaceutical company by 2030. This strategy, formulated in 2025, is built around three main pillars: Accelerate, Catalyze, and Expand, with clearly defined objectives and dedicated initiatives for each. The strategy was developed based on in-depth market studies to support Avalon’s transformation into a leading player in the pharmaceutical sector, ensuring sustainable growth, strengthening its competitive position, and creating a positive impact on the communities it serves. The development process included market analyses in collaboration with international consulting firms, comprehensive internal assessments, and advisory input from specialized organizations such as IQVIA and Strathaus.","This strategic direction (ACE Strategy) reinforces Avalon’s position as a leading company across various segments of the pharmaceutical industry. The company plans to expand its portfolio of prescription and over-the-counter medicines, with a focus on specialized areas such as oncology treatments. Through technology transfer agreements, Avalon will localize the production of major brands, supporting its expansion into the GCC, African, Middle Eastern, and Southeast Asian markets.",[21,40,138,283],{"id":22,"direction":23,"blocks":24},"u107a7","RightToLeftDirection",[25],{"id":26,"type":27,"text":28,"paragraphStyle":29,"runs":32},"u107a7:p0001","paragraph","",{"id":30,"name":31},"ParagraphStyle\u002Fmain text with bullets number w t","main text with bullets number w t",[33],{"character_style":34,"text":28,"token_types":37,"overrides":38,"properties":39},{"id":35,"name":36},"CharacterStyle\u002F$ID\u002F[No character style]","[No character style]",[],{},[],{"id":41,"direction":23,"blocks":42},"uc97b",[43,57,74,112,126],{"id":44,"type":27,"text":45,"paragraphStyle":46,"runs":49},"uc97b:p0001","Avalon’s “ACE” Strategy:\n",{"id":47,"name":48},"ParagraphStyle\u002Fheader%3ahaidline main text رئيسي ","header:haidline main text رئيسي ",[50],{"character_style":51,"text":45,"token_types":52,"overrides":55,"properties":56},{"id":35,"name":36},[53,54],"content","line_break",{},[],{"id":58,"type":27,"text":59,"paragraphStyle":60,"runs":63},"uc97b:p0002","Strengthening the Growth Path Towards 2030 and Beyond\n",{"id":61,"name":62},"ParagraphStyle\u002Fmain text group%3amain text med blue -mah","main text group:main text med blue -mah",[64],{"character_style":65,"text":59,"token_types":66,"overrides":67,"properties":68},{"id":35,"name":36},[53,54],{},[69],{"tag":70,"attributes":71,"text":73},"Leading",{"type":72},"unit","19",{"id":75,"type":27,"text":76,"paragraphStyle":77,"runs":80},"uc97b:p0003","Avalon is committed to implementing its “ACE” strategy, which forms the cornerstone of its vision to become a رbillion leading pharmaceutical company by 2030. This strategy, formulated in 2025, is built around three main pillars: Accelerate, Catalyze, and Expand, with clearly defined objectives and dedicated initiatives for each.\nThe strategy was developed based on in-depth market studies to support Avalon’s transformation into a leading player in the pharmaceutical sector, ensuring sustainable growth, strengthening its competitive position, and creating a positive impact on the communities it serves. The development process included market analyses in collaboration with international consulting firms, comprehensive internal assessments, and advisory input from specialized organizations such as IQVIA and Strathaus. \n",{"id":78,"name":79},"ParagraphStyle\u002Fmain text english","main text english",[81,90,104],{"character_style":82,"text":83,"token_types":84,"overrides":85,"properties":86},{"id":35,"name":36},"Avalon is committed to implementing its “ACE” strategy, which forms the cornerstone of its vision to become a ",[53],{},[87],{"tag":70,"attributes":88,"text":89},{"type":72},"14",{"character_style":91,"text":92,"token_types":93,"overrides":94,"properties":96},{"id":35,"name":36},"ر",[53],{"FontStyle":95},"Riyal",[97,99],{"tag":70,"attributes":98,"text":89},{"type":72},{"tag":100,"attributes":101,"text":103},"AppliedFont",{"type":102},"string","Saudi-Riyal",{"character_style":105,"text":106,"token_types":107,"overrides":108,"properties":109},{"id":35,"name":36},"billion leading pharmaceutical company by 2030. This strategy, formulated in 2025, is built around three main pillars: Accelerate, Catalyze, and Expand, with clearly defined objectives and dedicated initiatives for each.\nThe strategy was developed based on in-depth market studies to support Avalon’s transformation into a leading player in the pharmaceutical sector, ensuring sustainable growth, strengthening its competitive position, and creating a positive impact on the communities it serves. The development process included market analyses in collaboration with international consulting firms, comprehensive internal assessments, and advisory input from specialized organizations such as IQVIA and Strathaus. \n",[53,54,53,54],{},[110],{"tag":70,"attributes":111,"text":89},{"type":72},{"id":113,"type":27,"text":114,"paragraphStyle":115,"runs":118},"uc97b:p0004","This strategic direction (ACE Strategy) reinforces Avalon’s position as a leading company across various segments of the pharmaceutical industry. The company plans to expand its portfolio of prescription and over-the-counter medicines, with a focus on specialized areas such as oncology treatments. Through technology transfer agreements, Avalon will localize the production of major brands, supporting its expansion into the GCC, African, Middle Eastern, and Southeast Asian markets.\n",{"id":116,"name":117},"ParagraphStyle\u002Fmain text","main text",[119],{"character_style":120,"text":114,"token_types":121,"overrides":122,"properties":123},{"id":35,"name":36},[53,54],{},[124],{"tag":70,"attributes":125,"text":89},{"type":72},{"id":127,"type":27,"text":128,"paragraphStyle":129,"runs":130},"uc97b:p0005","As the company advances along its growth path, it has identified key areas for development to achieve higher operational efficiency. While certain segments, such as over-the-counter (OTC) medicines, reinforce Avalon’s leadership, the company aims to expand its presence in the prescription drug sector to strengthen its business. Additionally, in line with Vision 2030 objectives, Avalon seeks greater manufacturing autonomy by owning its technologies and managing its production facilities independently.\nTo ensure effective execution of its new strategy, the Strategy Management Office, officially launched in 2025, will lead all of the company’s strategic initiatives under the guidance of a team of specialized experts, ensuring effective coordination and accelerating growth plans. The office focuses on three main pillars: First, Aligning internal objectives and enhancing team integration by creating a connected work environment to ensure all stakeholders are aligned. Second, Overseeing the execution of the long-term strategy with a focus on key performance indicators. Third Implementing trans formative initiatives, such as digital transformation.",{"id":78,"name":79},[131],{"character_style":132,"text":128,"token_types":133,"overrides":134,"properties":135},{"id":35,"name":36},[53,54,53],{},[136],{"tag":70,"attributes":137,"text":89},{"type":72},{"id":139,"direction":23,"blocks":140},"u69a7",[141,166,191,211,223,246,267],{"id":142,"type":27,"text":143,"paragraphStyle":144,"runs":145},"u69a7:p0001","Expand\n",{"id":116,"name":117},[146,158],{"character_style":147,"text":148,"token_types":149,"overrides":150,"properties":154},{"id":35,"name":36},"Expand",[53],{"FillColor":151,"FontStyle":152,"PointSize":153},"Color\u002FWord_R7_G55_B99","Bold","10",[155],{"tag":70,"attributes":156,"text":157},{"type":72},"17",{"character_style":159,"text":160,"token_types":161,"overrides":162,"properties":163},{"id":35,"name":36},"\n",[54],{"FontStyle":152,"PointSize":153},[164],{"tag":70,"attributes":165,"text":157},{"type":72},{"id":167,"type":27,"text":168,"paragraphStyle":169,"runs":170},"u69a7:p0002","Expanding the company’s regional presence beyond the Saudi market.\n\n\n\n",{"id":116,"name":117},[171,182],{"character_style":172,"text":173,"token_types":174,"overrides":175,"properties":177},{"id":35,"name":36},"Expanding the company’s regional presence beyond the Saudi market.\n\n\n",[53,54,54,54],{"PointSize":176},"9",[178],{"tag":70,"attributes":179,"text":181},{"type":180},"enumeration","Auto",{"character_style":183,"text":160,"token_types":184,"overrides":185,"properties":188},{"id":35,"name":36},[54],{"FillColor":186,"FontStyle":187,"PointSize":153},"Color\u002F2nd","Medium",[189],{"tag":70,"attributes":190,"text":157},{"type":72},{"id":192,"type":27,"text":193,"paragraphStyle":194,"runs":195},"u69a7:p0003","Catalyze\n",{"id":116,"name":117},[196,204],{"character_style":197,"text":198,"token_types":199,"overrides":200,"properties":201},{"id":35,"name":36},"Catalyze",[53],{"FillColor":186,"FontStyle":152,"PointSize":153},[202],{"tag":70,"attributes":203,"text":157},{"type":72},{"character_style":205,"text":160,"token_types":206,"overrides":207,"properties":208},{"id":35,"name":36},[54],{"FillColor":186,"FontStyle":187,"PointSize":176},[209],{"tag":70,"attributes":210,"text":157},{"type":72},{"id":212,"type":27,"text":213,"paragraphStyle":214,"runs":215},"u69a7:p0004","Diversifying the product portfolio and launching new brands in promising therapeutic areas with limited competitiveness.\n\n\n\n",{"id":116,"name":117},[216],{"character_style":217,"text":213,"token_types":218,"overrides":219,"properties":220},{"id":35,"name":36},[53,54,54,54,54],{"PointSize":176},[221],{"tag":70,"attributes":222,"text":181},{"type":180},{"id":224,"type":27,"text":225,"paragraphStyle":226,"runs":227},"u69a7:p0005","Accelerate\n",{"id":116,"name":117},[228,237],{"character_style":229,"text":230,"token_types":231,"overrides":232,"properties":234},{"id":35,"name":36},"Accelerate",[53],{"FillColor":233,"FontStyle":152,"PointSize":153},"Color\u002Fu12899",[235],{"tag":70,"attributes":236,"text":157},{"type":72},{"character_style":238,"text":160,"token_types":239,"overrides":240,"properties":243},{"id":35,"name":36},[54],{"FillColor":241,"FontStyle":187,"PointSize":242},"Color\u002Fprimary","15",[244],{"tag":70,"attributes":245,"text":157},{"type":72},{"id":247,"type":27,"text":248,"paragraphStyle":249,"runs":250},"u69a7:p0006","Strategic execution to maximize returns from the existing portfolio within the Kingdom of Saudi Arabia.\n",{"id":116,"name":117},[251,259],{"character_style":252,"text":253,"token_types":254,"overrides":255,"properties":256},{"id":35,"name":36},"Strategic execution to maximize returns from the existing portfolio within the Kingdom of Saudi Arabia.",[53],{"PointSize":176},[257],{"tag":70,"attributes":258,"text":181},{"type":180},{"character_style":260,"text":160,"token_types":261,"overrides":262,"properties":264},{"id":35,"name":36},[54],{"ParagraphBreakType":263,"PointSize":176},"NextPage",[265],{"tag":70,"attributes":266,"text":181},{"type":180},{"id":268,"type":27,"text":28,"paragraphStyle":269,"runs":272},"u69a7:p0007",{"id":270,"name":271},"ParagraphStyle\u002Fmain text with bullets","main text with bullets",[273],{"character_style":274,"text":28,"token_types":275,"overrides":276,"properties":277},{"id":35,"name":36},[],{"PointSize":176},[278,280],{"tag":70,"attributes":279,"text":181},{"type":180},{"tag":100,"attributes":281,"text":282},{"type":102},"Gotham",{"id":284,"direction":23,"blocks":285},"uc935",[286,298,308,329,339,359,369,381],{"id":287,"type":27,"text":288,"paragraphStyle":289,"runs":292},"uc935:p0001","Detailed Strategic Pillars of Avalon Pharma\n",{"id":290,"name":291},"ParagraphStyle\u002Fheader%3ahaidline main text فرعي 1","header:haidline main text فرعي 1",[293],{"character_style":294,"text":288,"token_types":295,"overrides":296,"properties":297},{"id":35,"name":36},[53,54],{},[],{"id":299,"type":27,"text":300,"paragraphStyle":301,"runs":302},"uc935:p0002","Accelerate: Strengthening growth in existing sectors\n",{"id":61,"name":62},[303],{"character_style":304,"text":300,"token_types":305,"overrides":306,"properties":307},{"id":35,"name":36},[53,54],{},[],{"id":309,"type":27,"text":310,"paragraphStyle":311,"runs":312},"uc935:p0003","The “Accelerate” pillar focuses on enhancing operational efficiency and leveraging Avalon’s competitive advantages in the over-the-counter (OTC) pharmaceutical sector to drive growth and increase revenue. This includes expanding the product range by introducing new OTC items, offering innovative formulations across different therapeutic categories, extending the lifecycle of existing brands, and increasing their market reach.\nBy establishing strategic partnerships with major distributors and pharmacies, Avalon ensures efficient product availability and maximizes market opportunities. Additionally, the company aligns its production capabilities with growing demand to maintain its leadership in the Saudi healthcare market. This integrated approach contributes to sustainable growth and builds a strong foundation for the company’s future expansion.\n",{"id":78,"name":79},[313,321],{"character_style":314,"text":315,"token_types":316,"overrides":317,"properties":318},{"id":35,"name":36},"The “Accelerate” pillar focuses on enhancing operational efficiency and leveraging Avalon’s competitive advantages in the over-the-counter (OTC) pharmaceutical sector to drive growth and increase revenue. This includes expanding the product range by introducing new OTC items, offering innovative formulations across different therapeutic categories, extending the lifecycle of existing brands, and increasing their market reach.\nBy establishing strategic partnerships with major distributors and pharmacies, Avalon ensures efficient product availability and maximizes market opportunities. Additionally, the company aligns its production capabilities with growing demand to maintain its leadership in the Saudi healthcare market. This integrated approach contributes to sustainable growth and builds a strong foundation for the company’s future expansion.",[53,54,53],{},[319],{"tag":70,"attributes":320,"text":181},{"type":180},{"character_style":322,"text":160,"token_types":323,"overrides":324,"properties":326},{"id":35,"name":36},[54],{"FontStyle":325},"Regular",[327],{"tag":70,"attributes":328,"text":181},{"type":180},{"id":330,"type":27,"text":331,"paragraphStyle":332,"runs":333},"uc935:p0004","Catalyze: Diversifying the portfolio and launching new brands\n",{"id":61,"name":62},[334],{"character_style":335,"text":331,"token_types":336,"overrides":337,"properties":338},{"id":35,"name":36},[53,54],{},[],{"id":340,"type":27,"text":341,"paragraphStyle":342,"runs":343},"uc935:p0005","The “Catalyze” pillar focuses on expanding Avalon’s product portfolio and driving innovation by leveraging both local and global opportunities. This includes the annual introduction of advanced pharmaceutical compounds (injectable drugs, oncology treatments, and ophthalmology therapies), expanding high-demand over-the-counter (OTC) products, and developing specialized items that support localization objectives under Saudi Vision 2030.\nAvalon’s partnerships with leading global companies such as STADA and Adragos Pharma enhance its manufacturing and innovation capabilities, providing a competitive edge in the sector. By investing in research and development, offering advanced therapeutic solutions, and expanding strategic alliances, Avalon aims to meet the evolving needs of the healthcare market while strengthening its position as a leading domestic and global pharmaceutical company.\n",{"id":78,"name":79},[344,352],{"character_style":345,"text":346,"token_types":347,"overrides":348,"properties":349},{"id":35,"name":36},"The “Catalyze” pillar focuses on expanding Avalon’s product portfolio and driving innovation by leveraging both local and global opportunities. This includes the annual introduction of advanced pharmaceutical compounds (injectable drugs, oncology treatments, and ophthalmology therapies), expanding high-demand over-the-counter (OTC) products, and developing specialized items that support localization objectives under Saudi Vision 2030.\nAvalon’s partnerships with leading global companies such as STADA and Adragos Pharma enhance its manufacturing and innovation capabilities, providing a competitive edge in the sector. By investing in research and development, offering advanced therapeutic solutions, and expanding strategic alliances, Avalon aims to meet the evolving needs of the healthcare market while strengthening its position as a leading domestic and global pharmaceutical company.",[53,54,53],{},[350],{"tag":70,"attributes":351,"text":181},{"type":180},{"character_style":353,"text":160,"token_types":354,"overrides":355,"properties":356},{"id":35,"name":36},[54],{"FontStyle":325},[357],{"tag":70,"attributes":358,"text":181},{"type":180},{"id":360,"type":27,"text":361,"paragraphStyle":362,"runs":363},"uc935:p0006","Expand: Strengthening geographic presence and broadening market reach\n",{"id":61,"name":62},[364],{"character_style":365,"text":361,"token_types":366,"overrides":367,"properties":368},{"id":35,"name":36},[53,54],{},[],{"id":370,"type":27,"text":371,"paragraphStyle":372,"runs":373},"uc935:p0007","The “Expand” pillar reflects Avalon’s commitment to geographic growth by targeting new regional and international markets to strengthen its global presence. This strategy includes expanding exports to key markets such as the GCC countries, as well as entering untapped regions in Asia and Africa.\nAvalon leverages its extensive expertise and strategic partnerships to introduce high-quality, exclusive products that meet diverse healthcare needs. By investing in advanced manufacturing facilities and aligning with government incentives to support exports, the company ensures enhanced competitiveness and broader market reach. The “Expand” pillar embodies Avalon’s ambition to become a global leader in the pharmaceutical industry, while supporting the objectives of Saudi Vision 2030.\n",{"id":78,"name":79},[374],{"character_style":375,"text":371,"token_types":376,"overrides":377,"properties":378},{"id":35,"name":36},[53,54,53,54],{},[379],{"tag":70,"attributes":380,"text":181},{"type":180},{"id":382,"type":27,"text":160,"paragraphStyle":383,"runs":384},"uc935:p0008",{"id":116,"name":117},[385],{"character_style":386,"text":160,"token_types":387,"overrides":388,"properties":389},{"id":35,"name":36},[54],{},[390],{"tag":70,"attributes":391,"text":181},{"type":180},1790446649739]